|
Jul 25
|
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects
|
|
Jul 24
|
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
|
|
Jul 24
|
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
|
|
Jul 24
|
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
|
|
Jul 23
|
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
|
|
Jul 17
|
Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year?
|
|
Jul 16
|
INCY or TECH: Which Is the Better Value Stock Right Now?
|
|
Jul 14
|
India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement
|
|
Jul 11
|
High Growth Tech Stocks To Watch In US July 2025
|
|
Jul 10
|
Incyte’s Q2 2025 Earnings: What to Expect
|
|
Jul 9
|
William Blair Maintains ‘Hold’ Rating on Incyte Corporation (INCY), Citing Future Revenue Uncertainties
|
|
Jul 1
|
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
|
|
Jun 30
|
Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”
|
|
Jun 27
|
Incyte Stock Gets Relative Strength Rating Lift
|
|
Jun 27
|
Shell denies deal talks with BP, Micron reports Q3 beat: Morning Buzz
|
|
Jun 26
|
Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
|
|
Jun 26
|
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
|
|
Jun 24
|
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?
|
|
Jun 23
|
FDA Extends INCY's Application for Opzelura Label Expansion
|
|
Jun 23
|
5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call
|